335 related articles for article (PubMed ID: 21265993)
1. Risk stratification for benign prostatic hyperplasia (BPH) treatment.
Emberton M; Fitzpatrick JM; Rees J
BJU Int; 2011 Mar; 107(6):876-80. PubMed ID: 21265993
[TBL] [Abstract][Full Text] [Related]
2. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
3. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
[TBL] [Abstract][Full Text] [Related]
4. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
5. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management.
Barkin J
Can J Urol; 2011 Apr; 18 Suppl():14-9. PubMed ID: 21501546
[TBL] [Abstract][Full Text] [Related]
6. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
7. Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea.
Lee JY; Lee SH; Kim SJ; Kim CS; Lee HM; Kim CI; Chung BH
Urology; 2011 Jan; 77(1):171-6. PubMed ID: 20691464
[TBL] [Abstract][Full Text] [Related]
8. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
Trachtenberg J
BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
[TBL] [Abstract][Full Text] [Related]
9. Does the combination of an alpha1-adrenergic antagonist with a 5alpha-reductase inhibitor improve urinary symptoms more than either monotherapy?
Hollingsworth JM; Wei JT
Curr Opin Urol; 2010 Jan; 20(1):1-6. PubMed ID: 19881352
[TBL] [Abstract][Full Text] [Related]
10. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
11. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines.
Cornu JN; Cussenot O; Haab F; Lukacs B
Eur Urol; 2010 Sep; 58(3):450-6. PubMed ID: 20554374
[TBL] [Abstract][Full Text] [Related]
12. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
Marberger M
Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
[TBL] [Abstract][Full Text] [Related]
13. A multiinstitutional study of the effects of medical therapy for lower urinary symptoms on the perioperative outcomes of holmium laser enucleation of the prostate.
Warner JN; Nunez RN; Tyson MD; Viprakasit DP; Miller NL; Humphreys MR
Urology; 2011 Dec; 78(6):1385-90. PubMed ID: 21871654
[TBL] [Abstract][Full Text] [Related]
14. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.
Mirone V; Sessa A; Giuliano F; Berges R; Kirby M; Moncada I
Int J Clin Pract; 2011 Sep; 65(9):1005-13. PubMed ID: 21718399
[TBL] [Abstract][Full Text] [Related]
15. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
Kruep EJ; Phillips E; Hogue S; Eaddy M
Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
[TBL] [Abstract][Full Text] [Related]
16. An algorithm for medical management in male lower urinary tract symptoms.
Djavan B; Margreiter M; Dianat SS
Curr Opin Urol; 2011 Jan; 21(1):5-12. PubMed ID: 21045704
[TBL] [Abstract][Full Text] [Related]
17. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of medical treatment in benign prostatic hyperplasia.
Kim CI; Chang HS; Kim BK; Park CH
Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
[TBL] [Abstract][Full Text] [Related]
19. Impact of medical therapy on transurethral resection of the prostate: two decades of change.
Izard J; Nickel JC
BJU Int; 2011 Jul; 108(1):89-93. PubMed ID: 20883490
[TBL] [Abstract][Full Text] [Related]
20. Current role for combination therapy in male LUTS.
Chung DE; Kaplan SA
Arch Esp Urol; 2010 Jun; 63(5):323-32. PubMed ID: 20587837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
